Middle East And Africa Sjs Ten Treatment Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
 예측 기간 |
2023 –2030 |
 시장 규모(기준 연도) |
USD 320.21 Million |
 시장 규모(예측 연도) |
USD 471.24 Million |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
>중동 및 아프리카 SJS/TEN 치료 시장, 치료(약물, 지원 치료, 입원, 격리, 연고 및 기타), 진단(신체 검사, 피부 생검 , 병력, 혈액 검사, 배양 및 기타), 원인(특정 치료, 감염 및 기타), 투여 경로(경구, 비경구, 국소 및 기타), 약물 유형(브랜드 및 제네릭), 치료 영역(병용 요법 및 단일 요법), 환자 유형(노인, 성인 및 소아), 최종 사용자(병원, 전문 클리닉, 외래 수술 센터, 재택 치료 시설 및 기타), 유통 채널(소매 약국, 직접 입찰 및 기타) - 업계 동향 및 2030년까지의 예측.
중동 및 아프리카 SJS/TEN 치료 시장 분석 및 통찰력
스티븐스-존슨 증후군(SJS)과 독성 표피괴사증(TEN)은 이러한 질병이 드물기 때문에 치료 시장이 비교적 작습니다.
중동 및 아프리카 SJS/TEN 치료 시장은 약물이 주도하고 있으며, 약물은 이러한 질환의 주요 치료 형태입니다. 코르티코스테로이드, 정맥 면역글로불린(IVIG), 항생제는 SJS/TEN 치료에 가장 흔히 사용되는 약물입니다.
중동 및 아프리카 SJS/TEN 치료 시장은 2023년에서 2030년의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2023년에서 2030년의 예측 기간 동안 5.1%의 CAGR로 성장하고 있으며 2022년의 3억 2,021만 달러에서 2030년까지 4억 7,124만 달러에 도달할 것으로 분석합니다.
중동 및 아프리카 SJS/TEN 치료 시장 보고서는 시장 점유율, 새로운 개발 및 제품 파이프라인 분석, 국내 및 지역 시장 참여자의 영향, 새로운 수익 창출, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서의 분석 기회에 대한 세부 정보를 제공합니다. 분석 및 시장 시나리오를 이해하려면 분석가 브리핑을 위해 당사에 문의하세요. 당사 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드립니다. 다양한 지역의 개발도상국에 있는 소매점의 확장성과 사업 확장, 기계 및 약물 제품의 안전한 유통을 위한 공급업체와의 파트너십은 예측 기간 동안 시장 수요를 촉진한 주요 원동력입니다.
|
보고서 메트릭 |
세부 |
|
예측 기간 |
2023년부터 2030년까지 |
|
기준 연도 |
2022 |
|
역사적 연도 |
2021 (2015-2020까지 사용자 정의 가능) |
|
양적 단위 |
수익 (단위: USD 백만) |
|
다루는 세그먼트 |
치료(약물, 지원 치료, 입원, 격리, 연고 및 기타), 진단(신체 검사, 피부 생검, 병력, 혈액 검사, 배양 및 기타), 원인(특정 치료, 감염 및 기타), 투여 경로(경구, 비경구, 국소 및 기타), 약물 유형(브랜드 및 제네릭), 치료 영역(복합 치료 및 단일 치료), 환자 유형(노인, 성인 및 소아), 최종 사용자(병원, 전문 클리닉, 외래 수술 센터, 홈 케어 환경 및 기타), 유통 채널(소매 약국, 직접 입찰 및 기타) |
|
적용 국가 |
사우디 아라비아, 남아프리카 공화국, 바레인, 쿠웨이트, 오만, 카타르, UAE, 이집트, 이스라엘 및 기타 중동 및 아프리카 |
|
시장 참여자 포함 |
3M(미국), Cardinal Health(미국), BD(미국), Smith + Nephew(영국), Novartis AG(스위스), Amneal Pharmaceuticals LLC.(미국), Amgen Inc.(미국), Pfizer Inc.(미국), Colgate-Palmolive Company(미국), Merck & Co., Inc.(미국), Mölnlycke Health Care AB.(스웨덴), Xttrium Laboratories(미국), Schülke & Mayr GmbH(독일), ICPA Health Products Ltd(인도), Purdue Pharma LP(미국), eugia(Aurobindo Pharma 자회사), AdvaCare Pharma(미국) 등 |
시장 정의
스티븐스-존슨 증후군(SJS)과 독성 표피괴사증(TEN)은 드물지만 생명을 위협하는 피부 질환으로, 일반적으로 심각한 약물 반응으로 인해 발생합니다. 이러한 질환은 피부의 최상층이 아래층과 분리되어 신체 대부분을 덮을 수 있는 고통스러운 물집과 궤양을 유발합니다. SJS는 피부의 작은 부분에 영향을 미치는 반면, TEN은 피부의 더 큰 부분에 영향을 미칩니다.
SJS/TEN 치료의 정의는 이러한 질환을 관리하고 치료하도록 설계된 제품과 서비스를 말합니다. 시중에는 SJS/TEN 증상을 완화하고 환자의 삶의 질을 개선하는 데 도움이 되는 약물, 요법 및 기타 치료법이 있습니다. SJS/TEN 치료를 위한 약물 시장에는 증상을 완화하고 근본 원인을 치료하는 데 사용되는 여러 약물이 포함됩니다.
중동 및 아프리카 SJS/TEN 치료 시장 동향
이 섹션에서는 시장 동인, 이점, 제약 및 과제를 이해하는 것을 다룹니다. 이 모든 내용은 아래에서 자세히 설명합니다.
운전자
-
SJS/TEN의 유병률 및 발생률 증가
스티븐스-존슨 증후군(SJS)과 독성 표피괴사증(TEN)은 피부와 점막을 포함하는 심각하고 생명을 위협할 수 있는 질환입니다. SJS와 TEN은 질병 스펙트럼의 두 끝으로 간주되며, SJS는 더 가벼운 형태이고 TEN은 더 심각한 형태입니다. 이러한 질환의 특징은 강한 면역 반응으로 인해 표피(피부의 바깥층)와 진피(피부 아래의 층)가 분리되는 것입니다.
스티븐스-존슨 증후군(SJS)과 독성 표피괴사증(TEN)은 표피와 진피가 분리되는 것을 특징으로 하는 드물지만 심각한 피부 질환입니다. SJS/TEN의 발생률은 연간 100만 명당 약 1명으로 보고되었습니다. 그러나 최근 몇 년 동안 SJS/TEN의 발생률과 유병률에 대한 우려가 증가하고 있습니다.
-
SJS/TEN 치료를 위한 약물 개발의 진전
스티븐스-존슨 증후군(SJS)과 독성 표피괴사증(TEN)은 심각하고 잠재적으로 생명을 위협하는 질환으로 신속하고 적극적인 치료가 필요합니다. 현재 SJS/TEN을 치료할 수 있는 특정 약물이나 치료법은 없지만 약물 개발의 발전으로 인해 영향을 받는 환자에게 더 나은 치료 전략과 치료 결과가 나왔습니다. 그러나 SJS/TEN 치료를 위한 약물 개발을 위한 다양한 임상 시험이 진행 중입니다.
제지
-
SJS/TEN 치료와 관련된 높은 비용
SJS/TEN 치료가 비싼 주된 이유 중 하나는 집중적이고 장기적인 치료가 필요하기 때문입니다. SJS/TEN 환자는 종종 전문 화상 치료실에 입원해야 하며, 피부과 의사, 안과 의사, 중환자 치료 전문의를 포함한 의료진 팀으로부터 24시간 치료를 받습니다. 입원은 몇 주, 심한 경우 몇 달까지 지속될 수 있습니다. 이로 인해 병원 비용이 많이 들고 교통비, 숙박비, 식사비와 같은 관련 비용이 발생할 수 있습니다.
기회
-
SJS/TEN에 대한 효과적이고 안전한 치료법 개발
줄기세포 이식은 손상된 피부와 점막을 건강한 조직으로 대체하는 것을 목표로 하는 새로운 접근 방식입니다. 줄기세포를 환자의 피부에서 채취하여 배양한 후 손상된 부위에 다시 이식하는 자가 줄기세포 이식은 소규모 연구에서 유망한 결과를 보였습니다.
도전
- SJS/TEN 치료 승인에 대한 엄격한 정부 규정
SJS/TEN 치료 승인에 대한 엄격한 정부 규정은 제약 회사와 그들의 약물이 미국 식품의약국(FDA)이나 유럽 의약품 기관(EMA)과 같은 규제 기관으로부터 SJS/TEN 치료에 대한 승인을 받기 위해 거쳐야 하는 복잡하고 힘든 절차와 관련이 있습니다.
새로운 약물의 승인 절차에는 일반적으로 약물의 안전성과 효능을 평가하기 위한 인간을 대상으로 한 여러 단계의 임상 시험이 포함됩니다.
최근 개발 사항
- 2020년 6월, 아시아 태평양의 선도적 의료 기술 기업인 BD는 비상장 기업인 Straub Medical AG의 인수를 완료했다고 발표했습니다. 이 인수를 통해 회사는 Straub Medical AG의 귀중한 전문 지식과 경험을 추가하고 제품 포트폴리오를 확장했습니다. 이를 통해 회사는 시장에서 확장하고 성장할 수 있습니다.
- 2019년 1월, Mölnlycke Health Care AB는 상처 치료 역량을 더욱 강화하기 위해 MandJ Airlaid Products A/S를 인수합니다. 인수와 관련하여 MandJ와 그 직원은 Mölnlycke의 필수적인 부분이 될 것입니다. 이 인수는 Mölnlycke가 고급 상처 드레싱을 생산하는 데 필요한 에어 레이드 소재에 대한 공급을 확보하고 기존 및 미래 제품의 혁신과 제품 개발을 가속화하여 상처 치료 사업을 성장시키는 데 도움이 될 것입니다. 이를 통해 회사는 시장에서 확장하고 성장할 수 있습니다.
중동 및 아프리카 SJS/TEN 치료 시장 범위
중동 및 아프리카 SJS/TEN 치료 시장은 치료, 진단, 원인, 투여 경로, 약물 유형, 치료 유형, 환자 유형, 최종 사용자 및 유통 채널을 기준으로 9개의 주요 세그먼트로 분류됩니다. 세그먼트 간의 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.
중동 및 아프리카 SJS/TEN 치료 시장은 치료, 진단, 원인, 투여 경로, 약물 유형, 치료 유형, 환자 유형, 최종 사용자 및 유통 채널을 기준으로 9개의 주요 세그먼트로 분류됩니다.
치료
- 약물
- 지원 케어
- 연고
- 입원
- 격리
- 기타
중동 및 아프리카 SJS/TEN 치료 시장은 치료를 기준으로 약물, 지원 치료, 입원, 격리, 연고 및 기타로 구분됩니다.
진단
- 신체 검사
- 병력
- 피부 생검
- 혈액 검사
- 문화
- 기타
중동 및 아프리카 SJS/TEN 치료 시장은 진단을 기준으로 신체 검사, 피부 생검, 병력, 혈액 검사, 배양 및 기타로 구분됩니다.
원인
- 특정 치료
- 전염병
- 기타
중동 및 아프리카 SJS/TEN 치료 시장은 원인을 기준으로 특정 치료, 감염 및 기타로 구분됩니다.
투여 경로
- 경구
- 비경구적
- 뉴스 영화
- 기타
투여 경로를 기준으로 중동 및 아프리카 SJS/TEN 치료 시장은 경구, 비경구, 국소 및 기타로 구분됩니다.
약물 유형
- 브랜드화
- 일반적인
중동 및 아프리카 SJS/TEN 치료 시장은 약물 유형을 기준으로 브랜드 제품과 제네릭 제품으로 구분됩니다.
치료 유형
- 단일요법
- 복합치료
치료 유형을 기준으로 중동 및 아프리카 SJS/TEN 치료 시장은 복합 치료와 단일 치료로 구분됩니다.
환자 유형
- 소아과
- 성인
- 노인
중동 및 아프리카 SJS/TEN 치료 시장은 환자 유형을 기준으로 노인, 성인, 소아로 구분됩니다.
최종 사용자
- 병원
- 전문 클리닉
- 외래 수술 센터
- 홈케어 세팅
- 기타
중동 및 아프리카 SJS/TEN 치료 시장은 최종 사용자를 기준으로 병원, 전문 클리닉, 외래 수술 센터, 재택 치료 시설 및 기타로 구분됩니다.
유통 채널
- 직접 입찰
- 소매 약국
- 기타
중동 및 아프리카 SJS/TEN 치료 시장은 유통 채널을 기준으로 소매 약국, 직접 입찰 및 기타로 구분됩니다.
중동 및 아프리카 SJS/TEN 치료 시장 지역 분석/통찰력
중동 및 아프리카 SJS/TEN 치료 시장은 치료, 진단, 원인, 투여 경로, 약물 유형, 치료 유형, 환자 유형, 최종 사용자 및 유통 채널을 기준으로 9개의 주요 세그먼트로 분류됩니다.
이 시장 보고서에서 다루는 국가는 사우디아라비아, 남아프리카공화국, 바레인, 쿠웨이트, 오만, 카타르, UAE, 이집트, 이스라엘, 그리고 기타 중동 및 아프리카 국가입니다.
남아프리카공화국은 약물 개발 분야의 기술 발전으로 인해 우위를 점할 것으로 예상됩니다.
보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 중동 및 아프리카 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
경쟁 환경 및 중동 및 아프리카 SJS/TEN 치료 시장 점유율 분석
중동 및 아프리카 SJS/TEN 치료 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, R&D 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 승인, 제품 폭과 호흡, 응용 프로그램 우세 및 기술 수명선 곡선입니다. 제공된 위의 데이터 포인트는 중동 및 아프리카 SJS/TEN 치료 시장에 대한 회사의 초점과만 관련이 있습니다.
중동 및 아프리카 SJS/TEN 치료 시장에서 활동하는 주요 기업으로는 3M(미국), Cardinal Health(미국), BD(미국), Smith + Nephew(영국), Novartis AG(스위스), Amneal Pharmaceuticals LLC.(미국), Amgen Inc.(미국), Pfizer Inc.(미국), Colgate-Palmolive Company(미국), Merck & Co., Inc.(미국), Mölnlycke Health Care AB.(스웨덴), Xttrium Laboratories(미국), Schülke & Mayr GmbH(독일), ICPA Health Products Ltd(인도), Purdue Pharma LP(미국), eugia(Aurobindo Pharma의 자회사), AdvaCare Pharma(미국) 등이 있습니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TREATMENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 KEY TRENDS
4.2 COST OF TREATMENT
4.3 KEY PLAYERS STRATEGIES
4.4 LONG TERM GROWTH APPROACH
5 EPIDEMIOLOGY
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.2 DEMOGRAPHIC TRENDS
6.3 PATIENT FLOW DIAGRAM
6.4 KEY PRICING STRATEGIES
6.5 KEY PATIENT ENROLLMENT STRATEGIES
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE AND INCIDENCE OF SJS/TEN
7.1.2 ADVANCES IN DRUG DEVELOPMENT FOR SJS/TEN TREATMENT
7.1.3 INCREASING AWARENESS ABOUT THE RARE DISEASE SJS/TEN
7.1.4 GOVERNMENT INITIATIVES FOR SJS/TEN TREATMENT
7.2 RESTRAINTS
7.2.1 HIGH COST ASSOCIATED WITH THE TREATMENT OF SJS/TEN
7.2.2 LIMITED AVAILABILITY OF SPECIALIZED CARE FOR SJS/TEN TREATMENT
7.3 OPPORTUNITIES
7.3.1 DEVELOPING EFFECTIVE AND SAFE TREATMENT FOR SJS/TEN
7.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES FOR SJS/TEN TREATMENT
7.4 CHALLENGES
7.4.1 STRINGENT GOVERNMENT REGULATIONS FOR APPROVAL OF TREATMENT FOR SJS/TEN
7.4.2 LONG TERM COMPLICATIONS AND ADVERSE EFFECTS OF MEDICATIONS USED IN THE SJS/TEN TREATMENT
8 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY TREATMENT
8.1 OVERVIEW
8.2 MEDICATIONS
8.2.1 ANTIHISTAMINES
8.2.1.1 HYDROXYZINE
8.2.1.2 FEXOFENADINE
8.2.2 CORTICOSTEROID
8.2.2.1 DEXAMETHASONE
8.2.2.2 PREDNISOLONE
8.2.2.3 METHYLPREDNISOLONE
8.2.2.4 HYDROCORTISONE
8.2.2.5 OTHERS
8.2.3 ANTIBIOTICS
8.2.3.1 NAFCILLIN
8.2.3.2 GENTAMICIN
8.2.3.3 OTHERS
8.2.4 ANALGESICS
8.2.4.1 MORPHINE
8.2.4.2 FENTANYL CITRATE
8.2.4.3 OTHERS
8.2.5 ANTICOAGULANTS
8.2.6 ANTISEPTICS
8.2.6.1 CHLORHEXIDINE GLUCONATE
8.2.6.1.1 PERIOGARD
8.2.6.1.2 PERIDEX
8.2.6.1.3 AVAGARD
8.2.6.1.4 HIBICLENS
8.2.6.1.5 OTHERS
8.2.6.2 OCTENISEPT
8.2.6.3 POLYHEXANIDE SOLUTIONS
8.2.6.4 OTHERS
8.2.7 INTRAVENOUS IMMUNOGLOBULIN
8.2.8 CYCLOSPORINE
8.2.8.1 NEORAL
8.2.8.2 SANDIMMUNE
8.2.8.3 OTHERS
8.2.9 TUMOR NECROSIS FACTOR-ALPHA (TNF-Α)‒BLOCKING AGENT (ETANERCEPT)
8.2.10 OTHER TREATMENT
8.2.10.1 CYCLOPHOSPHAMIDE
8.2.10.2 N-ACETYLCYSTEINE
8.2.10.3 MONOCLONAL ANTIBODIES
8.2.10.4 THALIDOMIDE
8.3 SUPPORT CARE
8.3.1 INTRAVENOUS (IV) FLUID AND ELECTROLYTES
8.3.2 PAIN MANAGEMENT
8.3.2.1 LIDOCAINE
8.3.2.2 OTHERS
8.3.3 NUTRITION SUPPORT
8.3.4 ORAL CARE
8.3.5 PLASMAPHERESIS
8.3.6 BANDAGES
8.3.6.1 BIOLOGICAL DRESSING
8.3.6.1.1 ALLOGRAFT
8.3.6.1.2 XENOGRAFT
8.3.6.1.3 HOMOGRAFT
8.3.6.1.4 OTHERS
8.3.6.2 BIOSYNTHETIC DRESSING
8.3.6.3 SILVER IMPREGNATED DRESSING
8.4 HOSPITALIZATION
8.5 ISOLATION
8.6 OINTMENTS
8.6.1 BENZOCAINE
8.6.2 AMERICAINE
8.6.3 ANBESOL
8.6.4 CHIGGEREX PLUS
8.6.5 OTHERS
8.7 OTHERS
9 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS
9.1 OVERVIEW
9.2 PHYSICAL EXAM
9.3 SKIN BIOPSY
9.4 MEDICAL HISTORY
9.5 BLOOD TEST
9.5.1 COMPLETE BLOOD COUNT
9.5.2 ERYTHROCYTE SEDIMENTATION RATE
9.5.3 COAGULATION STUDIES
9.5.4 UREA AND ELECTROLYTES
9.5.5 LIVER FUNCTION TEST
9.6 CULTURES
9.7 OTHERS
10 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY CAUSE
10.1 OVERVIEW
10.2 SPECIFIC TREATMENT
10.3 INFECTION
10.4 OTHERS
11 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.3 PARENTERAL
11.3.1 INTRAVENOUS
11.3.2 SUBCUTANEOUS
11.3.3 OTHERS
11.4 TOPICAL
11.4.1 OINTMENTS
11.4.2 SOLUTION
11.4.3 CREAMS
11.4.4 OTHERS
11.5 OTHERS
12 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 BRANDED
12.2.1 NEORAL
12.2.2 SANDIMMUNE
12.2.3 VISTARIL
12.2.4 DURAMORPH
12.2.5 FENTORA
12.2.6 ENBREL
12.2.7 OTHERS
12.3 GENERIC
13 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY THERAPY TYPE
13.1 OVERVIEW
13.2 COMBINATION THERAPY
13.3 MONOTHERAPY
14 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE
14.1 OVERVIEW
14.2 GERIATRIC
14.2.1 FEMALE
14.2.2 MALE
14.3 ADULT
14.3.1 FEMALE
14.3.2 MALE
14.4 PEDIATRIC
15 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECIALTY CLINICS
15.4 AMBULATORY SURGICAL CENTER
15.5 HOMECARE SETTING
15.6 OTHERS
16 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 RETAIL PHARMACIES
16.2.1 HOSPITAL ASSOCIATED PHARMACIES
16.2.2 DRUG STORE
16.2.3 ONLINE PHARMACIES
16.3 DIRECT TENDERS
16.4 OTHERS
17 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY REGION
17.1 MIDDLE EAST AND AFRICA
17.1.1 SOUTH AFRICA
17.1.2 SAUDI ARABIA
17.1.3 BAHRAIN
17.1.4 U.A.E
17.1.5 KUWAIT
17.1.6 OMAN
17.1.7 QATAR
17.1.8 EGYPT
17.1.9 ISRAEL
17.1.10 REST OF MIDDLE EAST AND AFRICA
18 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 PFIZER INC.
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENT
20.2 NOVARTIS AG
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENT
20.3 MERCK & CO., INC.
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENT
20.4 AMNEAL PHARMACEUTICAL LLC.
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENT
20.5 AMGEN INC.
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 PRODUCT PORTFOLIO
20.5.4 RECENT DEVELOPMENT
20.6 ADVACARE PHARMA
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENT
20.7 BD
20.7.1 COMPANY SNAPSHOT
20.7.2 REVENUE ANALYSIS
20.7.3 PRODUCT PORTFOLIO
20.7.4 RECENT DEVELOPMENT
20.8 CARDINAL HEALTH
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENT
20.9 COLGATE-PALMOLIVE COMPANY
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORTFOLIO
20.9.4 RECENT DEVELOPMENT
20.1 EUGIA (SUBSIDIARY OF AUROBINDO PHARMA)
20.10.1 COMPANY SNAPSHOT
20.10.2 REVENUE ANALYSIS
20.10.3 PRODUCT PORTFOLIO
20.10.4 RECENT DEVELOPMENT
20.11 ICPA HEALTH PRODUCTS LTD
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENT
20.12 3M
20.12.1 COMPANY SNAPSHOT
20.12.2 REVENUE ANALYSIS
20.12.3 PRODUCT PORTFOLIO
20.12.4 RECENT DEVELOPMENT
20.13 MOLNLYCKE HEALTH CARE AB.
20.13.1 COMPANY SNAPSHOT
20.13.2 PRODUCT PORTFOLIO
20.13.3 RECENT DEVELOPMENT
20.14 PURDUE PHARMA L.P.
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENT
20.15 SCHULKE & MAYR GMBH
20.15.1 COMPANY SNAPSHOT
20.15.2 PRODUCT PORTFOLIO
20.15.3 RECENT DEVELOPMENT
20.16 SMITH + NEPHEW
20.16.1 COMPANY SNAPSHOT
20.16.2 REVENUE ANALYSIS
20.16.3 PRODUCT PORTFOLIO
20.16.4 RECENT DEVELOPMENT
20.17 XTTRIUM LABORATORIES
20.17.1 COMPANY SNAPSHOT
20.17.2 PRODUCT PORTFOLIO
20.17.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
표 목록
TABLE 1 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, PATENT ANALYSIS
TABLE 2 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA HOSPITALIZATION IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA ISOLATION IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA OINTMENTS IN JS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA PHYSICAL EXAM IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA SKIN BIOPSY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA MEDICAL HISTORY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA CULTURES IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA SPECIFIC TREATMENT IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA INFECTION IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA ORAL IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA TOPICAL IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA TOPICAL IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA BRANDED IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA BRANDED IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA GENERIC IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA COMBINATION THERAPY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA MONOTHERAPY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA GERAITRIC IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA ADULT IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 MIDDLE EAST AND AFRICA ADULT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 54 MIDDLE EAST AND AFRICA PEDIATRIC IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 56 MIDDLE EAST AND AFRICA HOSPITALS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 58 MIDDLE EAST AND AFRICA AMBULATORY SURGICAL CENTER IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 59 MIDDLE EAST AND AFRICA HOMECARE SETTING IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 60 MIDDLE EAST AND AFRICA OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 61 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 62 MIDDLE EAST AND AFRICA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 63 MIDDLE EAST AND AFRICA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 64 MIDDLE EAST AND AFRICA DIRECT TENDERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 65 MIDDLE EAST AND AFRICA OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 66 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 67 MIDDLE EAST AND AFRICA MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 68 MIDDLE EAST AND AFRICA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 69 MIDDLE EAST AND AFRICA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 70 MIDDLE EAST AND AFRICA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 71 MIDDLE EAST AND AFRICA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 72 MIDDLE EAST AND AFRICA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 73 MIDDLE EAST AND AFRICA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 74 MIDDLE EAST AND AFRICA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 75 MIDDLE EAST AND AFRICA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 76 MIDDLE EAST AND AFRICA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 77 MIDDLE EAST AND AFRICA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 78 MIDDLE EAST AND AFRICA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 79 MIDDLE EAST AND AFRICA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 80 MIDDLE EAST AND AFRICA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 81 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 82 MIDDLE EAST AND AFRICA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 83 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 84 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 85 MIDDLE EAST AND AFRICA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 86 MIDDLE EAST AND AFRICA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 87 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 88 MIDDLE EAST AND AFRICA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 89 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 90 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 91 MIDDLE EAST AND AFRICA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 92 MIDDLE EAST AND AFRICA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 93 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 94 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 95 MIDDLE EAST AND AFRICA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 96 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 97 SOUTH AFRICA MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 98 SOUTH AFRICA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 99 SOUTH AFRICA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 100 SOUTH AFRICA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 101 SOUTH AFRICA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 102 SOUTH AFRICA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 103 SOUTH AFRICA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 104 SOUTH AFRICA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 105 SOUTH AFRICA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 106 SOUTH AFRICA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 107 SOUTH AFRICA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 108 SOUTH AFRICA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 109 SOUTH AFRICA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 110 SOUTH AFRICA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 111 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 112 SOUTH AFRICA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 113 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 114 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 115 SOUTH AFRICA PRENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 116 SOUTH AFRICA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 117 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 118 SOUTH AFRICA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 119 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 120 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 121 SOUTH AFRICA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 122 SOUTH AFRICA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 123 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 124 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 125 SOUTH AFRICA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 126 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 127 SAUDI ARABIA MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 128 SAUDI ARABIA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 129 SAUDI ARABIA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 130 SAUDI ARABIA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 131 SAUDI ARABIA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 132 SAUDI ARABIA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 133 SAUDI ARABIA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 134 SAUDI ARABIA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 135 SAUDI ARABIA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 136 SAUDI ARABIA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 137 SAUDI ARABIA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 138 SAUDI ARABIA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 139 SAUDI ARABIA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 140 SAUDI ARABIA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 141 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 142 SAUDI ARABIA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 143 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 144 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 145 SAUDI ARABIA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 146 SAUDI ARABIA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 147 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 148 SAUDI ARABIA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 149 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 150 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 151 SAUDI ARABIA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 152 SAUDI ARABIA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 153 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 154 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 155 SAUDI ARABIA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 156 BAHRAIN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 157 BAHRAIN MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 158 BAHRAIN ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 159 BAHRAIN CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 160 BAHRAIN ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 161 BAHRAIN ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 162 BAHRAIN ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 163 BAHRAIN CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 164 BAHRAIN CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 165 BAHRAIN OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 166 BAHRAIN SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 167 BAHRAIN PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 168 BAHRAIN BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 169 BAHRAIN BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 170 BAHRAIN OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 171 BAHRAIN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 172 BAHRAIN BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 173 BAHRAIN SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 174 BAHRAIN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 175 BAHRAIN PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 176 BAHRAIN TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 177 BAHRAIN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 178 BAHRAIN BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 179 BAHRAIN SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 180 BAHRAIN SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 181 BAHRAIN GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 182 BAHRAIN ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 183 BAHRAIN SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 184 BAHRAIN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 185 BAHRAIN RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 186 U.A.E SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 187 U.A.E MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 188 U.A.E ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 189 U.A.E CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 190 U.A.E ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 191 U.A.E ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 192 U.A.E ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 193 U.A.E CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 194 U.A.E CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 195 U.A.E OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 196 U.A.E SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 197 U.A.E PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 198 U.A.E BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 199 U.A.E BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 200 U.A.E OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 201 U.A.E SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 202 U.A.E BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 203 U.A.E SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 204 U.A.E SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 205 U.A.E PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 206 U.A.E TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 207 U.A.E SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 208 U.A.E BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 209 U.A.E SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 210 U.A.E SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 211 U.A.E GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 212 U.A.E ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 213 U.A.E SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 214 U.A.E SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 215 U.A.E RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 216 KUWAIT SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 217 KUWAIT MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 218 KUWAIT ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 219 KUWAIT CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 220 KUWAIT ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 221 KUWAIT ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 222 KUWAIT ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 223 KUWAIT CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 224 KUWAIT CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 225 KUWAIT OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 226 KUWAIT SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 227 KUWAIT PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 228 KUWAIT BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 229 KUWAIT BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 230 KUWAIT OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 231 KUWAIT SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 232 KUWAIT BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 233 KUWAIT SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 234 KUWAIT SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 235 KUWAIT PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 236 KUWAIT TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 237 KUWAIT SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 238 KUWAIT BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 239 KUWAIT SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 240 KUWAIT SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 241 KUWAIT GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 242 KUWAIT ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 243 KUWAIT SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 244 KUWAIT SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 245 KUWAIT RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 246 OMAN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 247 OMAN MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 248 OMAN ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 249 OMAN CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 250 OMAN ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 251 OMAN ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 252 OMAN ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 253 OMAN CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 254 OMAN CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 255 OMAN OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 256 OMAN SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 257 OMAN PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 258 OMAN BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 259 OMAN BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 260 OMAN OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 261 OMAN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 262 OMAN BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 263 OMAN SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 264 OMAN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 265 OMAN PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 266 OMAN TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 267 OMAN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 268 OMAN BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 269 OMAN SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 270 OMAN SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 271 OMAN GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 272 OMAN ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 273 OMAN SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 274 OMAN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 275 OMAN RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 276 QATAR SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 277 QATAR MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 278 QATAR ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 279 QATAR CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 280 QATAR ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 281 QATAR ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 282 QATAR ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 283 QATAR CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 284 QATAR CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 285 QATAR OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 286 QATAR SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 287 QATAR PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 288 QATAR BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 289 QATAR BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 290 QATAR OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 291 QATAR SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 292 QATAR BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 293 QATAR SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 294 QATAR SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 295 QATAR PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 296 QATAR TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 297 QATAR SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 298 QATAR BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 299 QATAR SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 300 QATAR SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 301 QATAR GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 302 QATAR ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 303 QATAR SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 304 QATAR SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 305 QATAR RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 306 EGYPT SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 307 EGYPT MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 308 EGYPT ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 309 EGYPT CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 310 EGYPT ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 311 EGYPT ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 312 EGYPT ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 313 EGYPT CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 314 EGYPT CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 315 EGYPT OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 316 EGYPT SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 317 EGYPT PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 318 EGYPT BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 319 EGYPT BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 320 EGYPT OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 321 EGYPT SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 322 EGYPT BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 323 EGYPT SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 324 EGYPT SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 325 EGYPT PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 326 EGYPT TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 327 EGYPT SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 328 EGYPT BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 329 EGYPT SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 330 EGYPT SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 331 EGYPT GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 332 EGYPT ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 333 EGYPT SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 334 EGYPT SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 335 EGYPT RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 336 ISRAEL SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 337 ISRAEL MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 338 ISRAEL ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 339 ISRAEL CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 340 ISRAEL ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 341 ISRAEL ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 342 ISRAEL ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 343 ISRAEL CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 344 ISRAEL CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 345 ISRAEL OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 346 ISRAEL SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 347 ISRAEL PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 348 ISRAEL BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 349 ISRAEL BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 350 ISRAEL OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 351 ISRAEL SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 352 ISRAEL BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 353 ISRAEL SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 354 ISRAEL SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 355 ISRAEL PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 356 ISRAEL TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 357 ISRAEL SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 358 ISRAEL BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 359 ISRAEL SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 360 ISRAEL SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 361 ISRAEL GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 362 ISRAEL ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 363 ISRAEL SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 364 ISRAEL SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 365 ISRAEL RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 366 REST OF MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
그림 목록
FIGURE 1 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE AND INCIDENCE OF SJS/TEN ARE EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET IN THE FORECAST PERIOD FROM 2023 TO 2030
FIGURE 12 THE MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET IN THE FORECAST PERIOD OF 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET
FIGURE 14 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY TREATMENT, 2022
FIGURE 15 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY TREATMENT, 2023-2030 (USD MILLION)
FIGURE 16 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY TREATMENT, CAGR (2023-2030)
FIGURE 17 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 18 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, 2022
FIGURE 19 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, 2023-2030 (USD MILLION)
FIGURE 20 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, CAGR (2023-2030)
FIGURE 21 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, LIFELINE CURVE
FIGURE 22 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY CAUSE, 2022
FIGURE 23 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY CAUSE, 2023-2030 (USD MILLION)
FIGURE 24 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY CAUSE, CAGR (2023-2030)
FIGURE 25 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY CAUSE, LIFELINE CURVE
FIGURE 26 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 27 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
FIGURE 28 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 29 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 30 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY DRUG TYPE, 2022
FIGURE 31 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION)
FIGURE 32 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 33 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 34 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY THERAPY AREA, 2022
FIGURE 35 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY THERAPY AREA, 2023-2030 (USD MILLION)
FIGURE 36 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY THERAPY AREA, CAGR (2023-2030)
FIGURE 37 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY THERAPY AREA, LIFELINE CURVE
FIGURE 38 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, 2022
FIGURE 39 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, 2023-2030 (USD MILLION)
FIGURE 40 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, CAGR (2023-2030)
FIGURE 41 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 42 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY END USER, 2022
FIGURE 43 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 44 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY END USER, CAGR (2023-2030)
FIGURE 45 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 46 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 47 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 48 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 49 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 50 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: SNAPSHOT (2022)
FIGURE 51 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY COUNTRY (2022)
FIGURE 52 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY COUNTRY (2023 & 2030)
FIGURE 53 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY COUNTRY (2022 & 2030)
FIGURE 54 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY TREATMENT (2023-2030)
FIGURE 55 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: COMPANY SHARE 2022 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
